Key statistics dashboard for Climb Bio, Inc. (CLYM). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
Climb Bio, Inc. is a biopharmaceutical firm dedicated to crafting therapeutic solutions for inflammatory diseases driven by autoimmune responses. Its primary investigational asset is budoprutug, an anti-CD19 monoclonal antibody. This treatment is being advanced for a range of autoimmune conditions, including systemic lupus erythematosus, lupus nephritis, immune thrombocytopenia, and membranous nephropathy.
Stock Data
| Price | $14.11 |
| Market Cap | $808M |
| Enterprise Value | $765.2M |
| Beta | -0.20 |
| Exchange | NASDAQ |
| Country | US |
Valuation Multiples
| P/E Ratio | -17.04 |
| Price / Book | 4.50 |
| P/S | 0.00 |
| EV/EBITDA | -12.89 |
| EV/Sales | 0.00 |
| EV/FCF | -14.42 |
| P/FCF | -15.26 |
| Earnings Yield | -5.36% |
| FCF Yield | -6.57% |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 0.00% |
| EBIT Margin | 0.00% |
| EBITDA Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
| Return on Equity | -31.79% |
| Return on Assets | -23.40% |
| Return on Invested Capital | -26.89% |
| Return on Capital Employed | -26.94% |
Financial Health
| Current Ratio | 31.45 |
| Quick Ratio | 31.45 |
| Cash Ratio | 7.43 |
| Debt / Equity | 0.01 |
| Debt / Assets | 0.53% |
| Net Debt / EBITDA | 0.72 |
| Interest Coverage | 0.00 |
| Piotroski F-Score | 2 |
| Altman Z-Score | 19.34 |
Per-Share Data
| Revenue per share | 0.00 |
| Book Value per share | 3.15 |
| Cash per share | 2.40 |
| FCF per share | -0.70 |
| Tangible Book Value per share | 3.15 |
| Dividend per share | 0.00 |
Analyst Consensus
| Strong Buy | 0 |
| Buy | 5 |
| Hold | 0 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 5 |
| Avg rating (1-5) | 1.00 |
Related companies: ABOS · ACTU · AGEN · ANIX · ENTX · INO · MCRB
Explore sector: Healthcare · Biotechnology
More sections of CLYM: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks